Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
TORONTO, May 05, 2017 -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), announced today that Ferenc Somogyvari will be stepping down from the Company’s Board of Directors, and will be joining the Company’s Clinical and Scientific Advisory Board (“CSAB”), effective immediately.
The Board acknowledges Mr. Somogyvari's efforts and thanks him for his commitment and dedication to 3DS as a member of the Board of Directors over the past three years, and looks forward to his ongoing contributions as a new member of the CSAB. Mr. Somogyvari has served as an integral member of both the 3DS Board and, previously, as the Company’s founding CEO, and shares founder Dr. Sabine Mai's vision for advancing personalized medicine.
“We are honored to welcome Mr. Somogyvari to our Clinical and Scientific Advisory Board,” commented John Swift, Chairman of 3D Signatures Inc. “Ferenc is an experienced business leader in the optical, medical and biology industries, who will continue to be invaluable in guiding the development of this entirely new class of minimally invasive biomarkers.”
About 3DS
3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Hugh Rogers VP Corporate Finance 604-428-8842 [email protected] OR Stephen Kilmer Investor Relations 647-872-4849 [email protected]
